Background
In 2019, 15% of deaths in the UK were attributable to tobacco smoking [1]. Tobacco-related death and disease is not evenly distributed across the general population, with tobacco-related morbidities, such as cardiovascular disease, higher among people with a mental health condition (MHC) than those without [2, 3]. Indeed, tobacco smoking reduces life expectancy substantially among people with a MHC, especially those with a severe MHC [4]. The relationship between smoking and mental health is complex with evidence for causality in both directions depending on the mental health condition [5].
In 2014/2015 approximately 16.2% of adults in England smoked, 27% among adults with any MHC, and 40% among adults with a severe MHC [3, 6]. Smoking rates in the general population have since fallen to approximately 13.8% in 2020 [7], however, national smoking prevalence data for people with MHC are not regularly published; therefore, it is unknown if reductions have also been seen among this population. Higher smoking prevalence among people with MHCs is reported internationally, from representative surveys in the US (25.3%) [8], and Japan (36.7%)[9] and surveys among people with psychosis in Australia (66.1%) [10], or in MHC treatment in Singapore (39.5%)[11]. Psychological distress is distinctly different to a diagnosis of specific MHCs; however, it can indicate prevalence and severity of non-specific mental ill health symptoms [12]. Like MHC diagnosis, psychological distress is also associated with greater smoking rates [13].
Anzeige
Generally, people with MHCs are more likely to be heavy smokers, extract high levels of nicotine from cigarettes and have high cigarette dependence scores; and therefore, likely exposed to higher levels of harmful and potentially harmful substances in tobacco smoke and have greater difficulty quitting [14‐16].
Nicotine vaping products (e-cigarettes) are currently used by 8.3% of UK adults, of whom 65% exclusively vape and 35% vape and smoke (dual use) [17]. Vaping can help some people quit smoking [18, 19]. The UK NICE guidance on preventing uptake, promoting quitting and treating tobacco dependence recommends nicotine-containing e-cigarettes, or combination nicotine replacement therapy, or varenicline as a first-line smoking cessation aids [20], an approach that differs from other countries. Stopping smoking has been linked to reduced depression and anxiety, as well as improved psychological quality of life [5]. In 2016/17, among people with MHC who smoked in England, 23% also used e-cigarettes [21] and their use was positively associated with smoking cessation [22]. In the USA, vaping prevalence among people with MHCs (16.3%) is higher than without (6.5%) [8]. However, there are no recently published population-level data from England on e-cigarette or patterns of use or product use characteristics among people with MHCs or psychological distress. It is unknown if, like smoking, use patterns and product types differ between those with and without MHC and distress.
It is not uncommon for people to have multiple co-morbid MHCs, with the diagnosis of any MHC significantly increasing the risk of a diagnosis of another [23]. Data from the USA has found higher smoking prevalence among people with multiple MHC[8]; however, it is unclear if smoking characteristics, such as heaviness of smoking differ among those with one or more conditions [24, 25]. Moreover, it is unclear whether there are associations between co-morbid MHCs and vaping.
Therefore, this study aims to (1) report the prevalence of smoking, ex-smoking, vaping and dual use among those with and without a history of a single or multiple MHCs and with and without past month moderate or serious psychological distress; (2) assess differences in smoking and vaping characteristics among those with and without a history of single or multiple MHCs, and past month moderate or serious psychological distress.
Anzeige
Methods
Study design
Data were drawn from the ongoing Smoking Toolkit Study (STS), a monthly repeated cross-sectional survey of a representative sample of adults (≥16 years) in England, Scotland and Wales [26, 27]. Only data from England from participants aged 18 or over were used for this study. The STS uses a hybrid of random location and quota sampling to select a new sample of approximately 1700 adults from England each month. Locations were randomly selected from around 270,000 output areas in England stratified by a geodemographic classification of the population. Telephone interviews were conducted by landline and mobile using a standard landline random digit dialling (RDD), mobile RDD, and targeted mobile, with each eligible landline and mobile telephone number across GB had a random probability of selection proportionate to population distribution. To maximise responses, more landline sampling takes place earlier in the day, with more mobile sampling later in the day, therefore response rates are not appropriate to record. Questions regarding MHC were added to the survey in October 2020. Detailed methods are also available in Kock et al. (2021) [26].
Participants
Between October 2020 and April 2022, 30,766 people in England were surveyed. Those who did not complete the mental health questions (n=134) or selected ‘don’t know’ or ‘prefer not to say’ (n=822) in response to K6 variables were excluded. Those with ‘don’t know’ responses to smoking status (n=259) and missing or refused data for age (n=60) or socioeconomic status (n=1943), were also excluded. Adults who exclusively smoked tobacco products (pipes, cigars, shisha) other than cigarettes (n=464), were also excluded, reducing the sample to 27,437 for analyses. Type of cigarette smoked (roll your own or manufactured) was missing for 272 (of 3830 people who smoked), reducing the sample to 3358 for smoking analyses. Type of vaping product used was missing for 208 (of 1742 people who vaped), reducing the sample to 1534 for vaping analyses. (Additional file 1 Fig_S1)
Variables
Socio-demographic characteristics: Age, gender and occupation-based social codes (C2DE; ABC1). Gender was coded ‘Male’, ‘Female’, and ‘Identifies in another way’ for prevalence analysis. Due to small cell counts, gender was collapsed into ‘Female’ and ‘Other’ (Male and Identifies in another way) for smoking and vaping characteristics analysis.
Outcome variables
There were two self-reported mental health outcome measures.
1)
Self-reported MHC diagnosis, where participants were asked “Since the age of 16, which of the following, if any, has a doctor or health professional ever told you that you had?” followed by a list of ICD-10 recognised conditions. Responses were coded ‘Single MHC diagnosis’ or ‘Multiple MHC diagnosis’ (if more than one MHC diagnosis). Not responding, responding ‘Don’t know’, or ‘Prefer not to say’ were coded ‘Never MHC diagnosis’.
2)
Past month psychological distress was measured using the validated Kessler Psychological Distress Scale 6-item scale (K6 scale) [12, 28]. All participants were asked “During the past 30 days, about how often, if at all, did you feel… (a) Nervous, (b) Hopeless, (c) Restless or fidgety, (d) So depressed that nothing could cheer you up, (e) That everything was an effort, and (f) Worthless. Available responses were ‘All of the time’ (scored 4); ‘Most of the time’ (3); ‘Some of the time’ (2); ‘A little of the time’ (1); and ‘None of the time’ (0). A sum score was calculated In line with K6 guidance with a possible range from 0 to 24. Scores between 0 and 4 were coded ‘no or low distress’, 5 to 12 were coded as ‘moderate distress’ and 13 to 24 were coded ‘serious distress’ [12, 28] (Additional file 2 table_S1).
Predictor variables
Smoking: smoking status, and smoking characteristics including smoking frequency, Heaviness of Smoking Index (HSI) [29] (derived from cigarettes per day (CPD) and time to first cigarette (TTFC), and cigarette type (roll your own vs manufactured)(Additional file 2 table_S1).
Vaping: vaping status and vaping characteristics including vaping sessions per day, vaping product type, use of nicotine e-liquid and nicotine concentration of e-liquid (Additional file 2 table_S1).
Dual use was derived from smoking and vaping variables (Additional file 2 table_S1).
Analysis
Analyses were conducted using SPSS v27 and registered on Open Science Framework [30]. Descriptive statistics, but not multinomial regression analyses, were weighted using weights that have been created to match the English population profile on age, social grade, region, housing tenure, ethnicity, and working status within sex. Detailed methods are available in Kock et al. (2021) [26].
Weighted descriptive statistics report the prevalence of smoking, vaping and dual use, as well as frequency of use and product characteristics and demographic variables. Prevalence of smoking, vaping and dual use of and frequencies of smoking and vaping characteristics were also reported by a history of MHC and past month psychological distress.
For all multinomial regressions, MHC or past month psychological distress were the outcome variables.
For each of the two outcome variables, separate multinomial models were used to investigate associations with a series of separate models for each of the following explanatory variables:
1)
Prevalence, including current smoking status, current vaping status and current dual use.
2)
Smoking characteristics, including smoking frequency, HSI and cigarette type used.
3)
Vaping characteristics, including vaping frequency, vaping sessions per day, type of vaping product used and nicotine concentration used.
Vaping characteristics models were then repeated, stratifying for smoking to analyse dual users and exclusive vapers separately.
Anzeige
All analyses were adjusted for age, gender, and occupation. As dual use is common among people who vape or smoke, analyses for (1) smoking prevalence and (2) smoking characteristics were adjusted for current vaping; and analyses for (1) vaping prevalence and (3) vaping characteristics were adjusted for current smoking.
Sensitivity analyses
As there is still stigma in society around MHC diagnosis, which may have affected how participants responded to these questions, we conducted sensitivity analyses across all models to explore if differences occur if those who did not respond ‘don’t know’ or ‘prefer not to say’ to the MHC variable were coded ‘Ever MHC’ or if they were removed.
To explore the effect of excluding participants who smoked tobacco products (pipes, cigars, shisha) other than cigarettes, and in deviation from the pre-registered analysis, multinomial models were used to investigate associations between MHC and past month psychological distress and prevalence of ‘other’ tobacco use.
Results
Table 1 presents participant characteristics. Unadjusted analyses are presented in Additional file 2 tables S4-6.
Table 1
Weighted participant characteristics (N=27,437)
Total | No history of a MHC | One MHC | Two or more MHCs | No/low distress | Moderate distress | Serious distress | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | |
Total | 69.6 (69.1–70.1) | 19,465 | 13.6 (13.2–14.0) | 3816 | 16.8 (16.4–17.2) | 4681 | 71.6 (71.1–72.1) | 20,023 | 22.7 (22.2–23.2) | 6358 | 5.7 (5.4–6.0) | 1580 | ||
Gender | ||||||||||||||
Female | 50.8 (50.2–51.4) | 14,258 | 46.5 (45.8–47.2) | 9058 | 58.6 (57.0–60.2) | 2237 | 62.5 (61.1–63.9) | 2927 | 48.2 (47.6–48.9) | 9659 | 56.8 (55.6–58.0) | 3612 | 60.1 (57.6–62.5) | 950 |
Male | 48.6 (48.0–49.2) | 13,653 | 53.2 (52.5–53.9) | 10,353 | 40.5 (38.9–42.0) | 1544 | 36.2 (34.8–37.5) | 1692 | 51.5 (50.8–52.3) | 10,311 | 42.3 (41.0–43.5) | 2685 | 37.5 (35.1–40.0) | 593 |
In another way | 0.6 (0.5–0.7) | 155 | 0.3 (0.2–0.4) | 54 | 0.9 (0.6–1.3) | 35 | 1.3 (1.0–1.7) | 62 | 0.3 (0.02–0.04) | 53 | 0.9 (0.7–1.2) | 60 | 2.4 (1.7–3.3) | 38 |
Socioeconomic status | ||||||||||||||
ABC1 | 54.4 (53.8–55.0) | 15,264 | 56.5 (55.8–57.2) | 11,004 | 54.9 (53.3–56.5) | 2095 | 45.6 (44.1–47.0) | 2133 | 57.2 (56.5–58.9) | 11,453 | 51.3 (50.1–52.5) | 3260 | 32.8 (30.5–35.2) | 519 |
C2DE | 45.6 (45.0–46.2) | 12,803 | 43.5 (42.8–44.2) | 8461 | 45.1 (43.5–46.7) | 1721 | 54.4 (53.0–55.9) | 2547 | 42.8 (42.1–43.5) | 8570 | 48.7 (47.5–50.0) | 3098 | 67.2 (64.8–69.5) | 1062 |
Age | M=49.1 SD=18.5 | M=50.7 SD=18.5 | M=48.8 SD=17.3 | M=43.0 SD=16.7 | M=52.0 SD=18.0 | M=42.6 SD=18.1 | M=39.6 SD=16.9 | |||||||
Smoking status | ||||||||||||||
Current smoker | 15.0 (14.6–15.4) | 4202 | 12.0 (11.5–12.5) | 2339 | 16.6 (15.4–17.8) | 632 | 26.3 (25–27.6) | 1231 | 12.0 (11.5–12.5) | 2401 | 19.8 (18.8–20.8) | 1257 | 34.5 (32.2–36.8) | 4203 |
Quit smoking in the past year | 2.3 (2.1–2.5) | 651 | 1.8 (1.6–2.0) | 346 | 2.9 (2.4–3.4) | 111 | 4.1 (3.5–4.7) | 194 | 1.0 (0.9–1.1) | 376 | 3.2 (2.8–3.6) | 205 | 4.4 (3.4–5.4) | 69 |
Quit smoking more than a year ago | 23.9 (23.4–24.4) | 6692 | 23.2 (22.6–23.8) | 4508 | 27.0 (25.6–28.4) | 1029 | 24.7 (23.5–25.9) | 1155 | 25.1 (24.5–25.7) | 5029 | 21.5 (20.5–22.5) | 1366 | 18.8 (16.9–20.7) | 297 |
Never smoked | 58.7 (58.1–59.3) | 16,415 | 63.0 (62.3–63.7) | 12,271 | 53.6 (52.0–55.2) | 2044 | 44.9 (43.5–46.3) | 2100 | 61.0 (60.3–61.7) | 12,217 | 55.5 (54.3–56.7) | 3530 | 34.5 (32.2–36.8) | 545 |
Vaping status | ||||||||||||||
Current vaper | 6.9 (6.6–7.2) | 1936 | 5.1 (4.8–5.4) | 989 | 7.9 (7.0–8.8) | 300 | 13.8 (12.8–14.8) | 647 | 5.5 (5.2–5.8) | 1103 | 9.0 (8.3–9.7) | 573 | 16.4 (14.6–18.2) | 260 |
Non-vaper | 93.1 (92.8–93.4) | 26,025 | 94.9 (94.6–95.2) | 18,476 | 92.1 (91.2–93) | 3516 | 86.2 (85.2–87.2) | 4033 | 94.5 (94.2–94.8) | 18,920 | 91.0 (90.3–91.7) | 5784 | 83.6 (81.8–85.4) | 1321 |
Dual use status | ||||||||||||||
Daily dual | 1.3 (1.2–1.4) | 365 | 0.8 (0.7–0.9) | 158 | 1.5 (1.1–1.9) | 56 | 3.2 (2.7–3.7) | 151 | 0.9 (0.8–1) | 181 | 1.7 (1.4–2.0) | 110 | 4.7 (3.7–5.7) | 74 |
Non-daily dual | 0.4 (0.3–0.5) | 112 | 0.3 (0.2–0.4) | 10 | 0.3 (0.1–0.5) | 10 | 0.7 (0.5–0.9) | 34 | 0.3 (0.2–0.4) | 60 | 0.5 (0.3–0.7) | 33 | 1.1 (0.6–1.6) | 18 |
Predominate smoker | 1.0 (0.9–1.1) | 287 | 0.7 (0.6–0.8) | 142 | 1.0 (0.7–1.3) | 38 | 2.3 (1.9–2.7) | 107 | 0.7 (0.6–0.8) | 147 | 1.6 (1.3–1.9) | 99 | 2.6 (1.8–3.4) | 41 |
Predominate vaper | 0.6 (0.5–0.7) | 154 | 0.4 (0.3–0.5) | 82 | 0.7 (0.4–1.0) | 27 | 1.0 (0.7–1.3) | 45 | 0.5 (0.4–0.6) | 92 | 0.7 (0.5–0.9) | 45 | 1.1 (0.6–1.6) | 18 |
Exclusive smoker | 11.7 (11.3–12.1) | 3285 | 9.7 (9.3–10.1) | 1890 | 13.1 (12–14.2) | 501 | 19.1 (18.0–20.2) | 894 | 9.6 (9.2–10) | 1922 | 15.2 (14.3–16.1) | 969 | 24.9 (22.8–27.0) | 394 |
Exclusive vaper | 3.6 (3.4–3.8) | 1019 | 2.8 (2.6–3.0) | 539 | 4.5 (3.8–5.2) | 170 | 6.6 (5.9–7.3) | 310 | 3.1 (2.9–3.3) | 625 | 4.5 (4.0–5.0) | 282 | 6.8 (5.6–8.0) | 108 |
Never/Ex smoker/Vaper | 81.3 (80.8–81.8) | 22,740 | 85.2 (84.7–85.7) | 16,586 | 79.0 (77.7–80.3) | 3015 | 67.1 (65.8–68.4) | 3139 | 84.9 (84.4–85.4) | 16,998 | 75.7 (74.6–76.8) | 4815 | 58.7 (56.3–61.1) | 927 |
The average participant age was 49 (SD=18.5), and there were broadly similar proportions of female (50.8%) and male (48.6%) participants, with few participants identifying their gender in another way (0.6%). There were marginally more people from a higher socioeconomic background (ABC1 54.4%) than lower socioeconomic backgrounds (C2DE 45.6%). The majority (69.6%) of participants reported no history of a MHC, 13.6% reported a history of one MHC and 16.8% a history of multiple MHCs. Among those with a history of a single MHC, 62.0% reported no/low distress, 31.6% moderate and 6.4% serious distress. Among those with a history of multiple MHCs, 33.6% reported no/low distress, 43.9% moderate and 22.5% serious distress.
Smoking status and characteristics by MHC and psychological distress
Those who were currently smoking were significantly more likely to report a history of a single (15.0%, AOR=1.62, 95% CI=1.46-1.81, p<.001) or multiple MHCs (29.3%, AOR=2.51, 95% CI=2.28-2.75, p<.001) compared to those who had never smoked (single MHC 12.4%; multiple MHC 12.8%) (Table 2). Current smoking was most prevalent among those with a history of a substance misuse disorder (55.3%), a personality disorder (50.9%), or psychosis (43.1%)(Additional file 2 table_S2).
Table 2
Associations between smoking, vaping and dual use status and mental health conditions and psychological distress, unweighted (N=27,437)
No history of MHC d | One MHC d | Two or more MHCs d | No/low past month distress e | Moderate past month distress e | Serious past month distress e | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% (95% CI) | % (95% CI) | AOR (95% CI) | p | % (95% CI) | AOR (95% CI) | p | % (95% CI) | % (95% CI) | AOR (95% CI) | p | % (95% CI) | AOR (95% CI) | p | |
Smoking a | ||||||||||||||
Never smoker | 74.8 (74.1–75.5) | 12.4 (12.0–13.0) | 1 | Ref | 12.8 (12.3–13.3) | 1 | Ref | 74.4 (73.8–75.1) | 21.5 (20.9–22.1) | 1 | Ref | 4.1 (3.8–4.4) | 1 | Ref |
Ex-smoker | 66.1 (65.0–67.2) | 15.5 (14.7–16.3) | 1.51 (1.39–1.64) | <.001 | 18.4 (17.5–19.3) | 1.81 (1.67–1.97) | <.001 | 73.6 (72.7–74.6) | 21.4 (20.5–22.3) | 1.22 (1.13–1.31) | <.001 | 5.0 (4.5–5.5) | 1.50 (1.30–1.74) | <.001 |
Current smoker | 55.7 (54.2–57.2) | 15.0 (13.9–16.1) | 1.62 (1.46–1.81) | <.001 | 29.3 (27.9–30.7) | 2.51 (2.28–2.75) | <.001 | 57.1 (55.7–58.6) | 29.9 (28.5–31.3) | 1.53 (1.40–1.67) | <.001 | 13.0 (12.0–14.0) | 2.97 (2.59–3.42) | <.001 |
Vaping b | ||||||||||||||
Non-vaper | 71.0 (69.0–73.0) | 13.5 (12–15) | 1 | Ref | 15.5 (13.9–17.1) | 1 | Ref | 72.7 (72.2–73.2) | 22.2 (20.3–24.1) | 1 | Ref | 5.1 (4.1–6.1) | 1 | Ref |
Current vaper | 51.1 (50.5–51.7) | 15.5 (15.1–15.9) | 1.28 (1.11–1.48) | .001 | 33.4 (32.8–34.0) | 1.66 (1.47–1.87) | <.001 | 57.0 (54.7–59.2) | 29.6 (29–30.2) | 1.16 (1.03–1.31) | .015 | 13.4 (13.0–13.8) | 1.58 (1.33–1.88) | <.001 |
Dual use c | ||||||||||||||
Dual user | 49.0 (45.8–52.2) | 14.2 (12–16.6) | 1 | Ref | 36.8 (33.7–39.9) | 1 | Ref | 52.2 (48.9–55.5) | 31.4 (28.4–34.4) | 1 | Ref | 16.4 (14.0–18.8) | 1 | Ref |
Exclusive Vaper | 52.9 (49.8–56) | 16.7 (14.4–19.0) | 1.01 (0.77–1.32) | .965 | 30.4 (27.6–33.2) | 0.78 (0.63–0.97) | .028 | 74.7 (74.2–75.3) | 28.1 (25.3–30.9) | 0.78 (0.63–0.97) | .025 | 10.6 (8.7–12.5) | 0.61 (0.45–0.83) | .001 |
Exclusive Smoker | 57.5 (55.8–59.2) | 15.3 (14.1–16.5) | 0.85 (0.68–1.07) | .172 | 27.2 (25.7–28.7) | 0.67 (0.56–0.80) | <.001 | 58.5 (57.8–59.2) | 29.5 (27.9–31.1) | 0.87 (0.73–1.04) | .133 | 12.0 (10.9–13.1) | 0.74 (0.59–0.94) | .013 |
Never/ex-smoker/vaper | 72.9 (72.3–73.5) | 13.3 (12.9–13.7) | 0.58 (0.47–0.71) | <.001 | 13.8 (13.4–14.2) | 0.31 (0.26–0.36) | <.001 | 74.7 (74.1–75.3) | 21.2 (20.7–21.7) | 0.60 (0.51–0.70) | <.001 | 4.1 (3.8–4.4) | 0.26 (0.21–0.33) | <.001 |
Anzeige
Those who smoked daily, and those with a higher HSI score were significantly more likely to report a history of multiple or a single MHC compared to those who were smoking non-daily or had a low HSI score. Those who smoked manufactured cigarettes were less likely to report a history of multiple or a single MHC than no history of MHCs than those who smoked roll-your-own cigarettes (Table 3). Smoking characteristics varied by type of MHC; however, sample sizes were small (Additional file 2 table_S3a).
Table 3
Associations between smoking characteristics and mental health conditions and past month psychological distress among current smokers, unweighted (n=3358)
No history of MHCa | One MHC a | Two or more MHCs a | No/low distress b | Moderate distressb | Serious distress b | |||||
|---|---|---|---|---|---|---|---|---|---|---|
% (N) | % (N) | AOR (95% CI) | % (N) | AOR (95% CI) | % (N) | % (N) | AOR (95% CI) | % (N) | AOR (95% CI) | |
Smoking frequency | ||||||||||
Non-daily smoker | 60.5 (517) | 14.3 (122) | 1 | 25.2(215) | 1 | 59.4 (508) | 29.9 (255) | 1 | 10.7 (91) | 1 |
Daily smoker | 54.1 (1652) | 15.0 (457) | 1.29 (1.01–1.64) | 30.9(945) | 1.68 (1.37–2.05) | 56.4 (1721) | 30.1 (918) | 1.29 (1.06–1.56) | 13.6 (415) | 1.84 (1.38–2.44) |
Type of cigarette | ||||||||||
Roll your own | 49.1 (906) | 15.3 (283) | 1 | 35.6(658) | 1 | 51.1 (944) | 32.5 (601) | 1 | 16.4 (302) | 1 |
Manufactured | 63.2 (1136) | 14.3 (257) | 0.74 (0.61–0.91) | 22.5(404) | 0.57 (0.48–0.67) | 64.6 (1162) | 26.6 (478) | 0.75 (0.63–0.88) | 8.8 (158) | 0.57 (0.45–0.72) |
Roll your own and manufactured | 48.1 (127) | 14.8 (39) | 1.19 (0.8–1.76) | 37.1(98) | 1.03 (0.75–1.42) | 47.0 (124) | 35.6 (95) | 1.21 (0.89–1.65) | 17.4 (46) | 1.02 (0.68–1.55) |
Heaviness of smoking index (daily smokers n=3054) | ||||||||||
High | 32.2 (36) | 20.5 (23) | 1 | 47.3(53) | 1 | 47.3 (53) | 32.2 (36) | 1 | 20.5 (23) | 1 |
Medium | 51.6 (876) | 16.2 (276) | 0.48 (0.27–0.85) | 32.2(547) | 0.31 (0.19–0.50) | 55.8 (948) | 28.5 (485) | 0.68 (0.42–1.10) | 15.7 (267) | 0.42 (0.25–0.73) |
Low | 59.1 (714) | 12.7 (153) | 0.32 (0.18–0.58) | 28.2(341) | 0.22 (0.13–0.36) | 57.9 (700) | 32.0 (386) | 0.68 (0.42–1.11) | 10.1 (122) | 0.23 (0.13–0.41) |
Don’t know | 74.3 (26) | 14.3 (5) | 0.26 (0.08–0.87) | 11.4(4) | 0.09 (0.03–0.30) | 57.2 (20) | 31.4 (11) | 0.85 (0.34–2.15) | 11.4 (4) | 0.31 (0.08–1.21) |
Vaping status and characteristics by MHC and psychological distress
Those who were currently vaping were significantly more likely to report a history of a single (15.5%, AOR=1.28, 95% CI=1.11–1.48, p<.001) or multiple MHCs (33.4%, AOR=1.66, 95% CI=1.47–1.87, p<.001) compared to those not currently vaping (single MHC 13.5%; multiple MHC 15.5%) (Table 2). Current vaping was most prevalent among those with a history a substance misuse disorder (23.9%), a personality disorder (20.8%) or psychosis (19.7%) (Additional file 2 table_S2).
Among those who were currently vaping, there was no statistically significant association between frequency of vaping (vaping daily or non-daily) or vaping sessions per day, type of vaping product used or nicotine use or nicotine concentration and a history of MHCs (Table 4). Unadjusted analyses are presented in Additional file 2 tables S4 and S6. Vaping characteristics varied by type of MHC; however, sample sizes were too small to test for significance (Additional file 2 table_S3b).
Table 4
Associations between vaping characteristics and mental health conditions and past month psychological distress among current vapers, unweighted (n=1534)
No history of a MHC a | One MHC a | Two or more MHCs a | No/low distress b | Moderate distress b | Serious distress b | |||||
|---|---|---|---|---|---|---|---|---|---|---|
% (N) | % (N) | AOR (95% CI) | % (N) | AOR (95% CI) | % (N) | % (N) | AOR (95% CI) | % (N) | AOR (95% CI) | |
Frequency of vaping | ||||||||||
Daily | 50.0 (579) | 16.5 (191) | 1 | 33.5 (387) | 1 | 58.6 (677) | 27.9 (323) | 1 | 13.5 (157) | 1 |
Non-daily | 54.9 (293) | 13.1 (70) | 0.81 (0.59–1.11) | 32.0 (171) | 0.83 (0.65–1.08) | 53.6 (286) | 33.7 (180) | 1.35 (1.06–1.73) | 12.7 (68) | 0.96 (0.67–1.37) |
Vaping sessions per day (daily vapers only N=1042) | ||||||||||
12+ times a day | 48.0 (179) | 18.2 (68) | 1 | 33.8 (126) | 1 | 61.1 (228) | 29.5 (110) | 1 | 9.4 (35) | 1 |
5–11 times a day | 50.6 (214) | 16.8 (71) | 0.84 (0.55–1.29) | 32.6 (138) | 0.71 (0.50–1.01) | 56.7 (240) | 27.7 (117) | 1.02 (0.71–1.45) | 15.6 (66) | 1.57 (0.95–2.62) |
1–4 times a day | 51.7 (186) | 14.2 (51) | 0.73 (0.46–1.16) | 34.1 (123) | 0.70 (0.48–1.02) | 57.9 (209) | 26.6 (96) | 0.88 (0.60–1.28) | 15.5 (56) | 1.29 (0.75–2.22) |
Device type | ||||||||||
Mod | 52.5 (171) | 13.5 (44) | 1 | 34.0 (111) | 1 | 61.3 (200) | 27.0 (88) | 1 | 11.7 (122) | 1 |
Pod | 53.8 (91) | 12.7 (30) | 0.94 (0.56–1.58) | 33.5 (79) | 0.89 (0.59–1.33) | 56.2 (132) | 27.2 (64) | 1.15 (0.76–1.73) | 16.6 (390 | 1.51 (0.85–2.66) |
Tank | 50.2 (483) | 17.8 (172) | 1.36 (0.93–2.00) | 32.0 (308) | 0.98 (0.72–1.33) | 58.5 (563) | 28.9 (278) | 1.07 (0.79–1.45) | 12.6 (122) | 1.11 (0.71–1.73) |
Disposable | 55.2 (91) | 8.4 (14) | 0.62 (0.32–1.21) | 36.4 (60) | 0.69 (0.43–1.08) | 40.6 (67) | 43.6 (72) | 1.70 (1.07–2.68) | 15.8 (260 | 1.30 (0.69–2.46) |
Currently using nicotine e-liquid | ||||||||||
No | 50.5 (97) | 15.6 (30) | 1 | 33.9 (65) | 1 | 58.5 (113) | 26.5 (51) | 1 | 15.0 (29) | 1 |
Yes | 51.7 (774) | 15.4 (231) | 1.06 (0.67–1.68) | 32.9 (492) | 0.9 (0.63–1.29) | 56.7 (850) | 30.2 (452) | 1.19 (0.81–1.73) | 13.1 (196) | 0.78 (0.48–1.24) |
Nicotine concentration (vapers current using nicotine only =1370) | ||||||||||
20mg+ | 48.3 (72) | 12.8 (19) | 1 | 38.9 (58) | 1 | 41.6 (62) | 31.6 (47) | 1 | 26.8 (40) | 1 |
12–19 mg | 49.7 (188) | 19.0 (72) | 1.6 (0.87–2.96) | 31.3 (118) | 1.08 (0.67–1.72) | 55.0 (208) | 32.2 (122) | 1.16 (0.71–1.87) | 12.8 (48) | 0.65 (0.36–1.18) |
7–11mg | 46.9 (82) | 14.2 (25) | 1.09 (0.53–2.24) | 38.9 (68) | 1.22 (0.71–2.07) | 59.1 (411) | 27.3 (48) | 0.75 (0.42–1.31) | 13.6 (24) | 0.53 (0.26–1.06) |
1–6mg | 51.6 (354) | 14.9 (102) | 1.17 (0.65–2.11) | 33.5 (230) | 1.12 (0.73–1.72) | 59.9 (411) | 29.5 (202) | 0.82 (0.52–1.28) | 10.6 (73) | 0.40 (0.23–0.70) |
Don’t know | 68.9 (84) | 11.4 (14) | 0.68 (0.31–1.48) | 19.7 (24) | 0.51 (0.28–0.95) | 59.5 (72) | 28.9 (35) | 1.14 (0.63–2.05) | 11.6 (14) | 0.63 (0.29–1.37) |
Anzeige
Those who were vaping non-daily were more likely to report moderate but not serious distress compared to those who were vaping daily. Disposables were also more likely to be used among people with moderate, but not serious, distress. Those vaping 1–6 mg/mL of nicotine were less likely to report serious distress compared to those vaping 20 mg/mL or more. There were no statistically significant associations between vaping sessions per day, current use of nicotine and past month distress (Table 4) (Additional file 2 table_S5).
Exclusive vaping characteristics by MHC and psychological distress
When vaping characteristics were stratified by exclusive vaping and dual use, those who were exclusively vaping and who vaped 1–6 mg/mL or 12–19 mg/mL of nicotine were significantly more likely to report a history of multiple MHCs than those who vaped 20mg/mL or more. Those who vaped 5–11 times a day were also more likely to report serious distress than those who vaped over 12 times a day. All other associations were non-significant (Additional file 2 table_S7).
Dual use by MHC and psychological distress
Those who were not currently smoking or vaping were significantly less likely to report a history of a single MHC (13.3%, AOR=0.58, 95% CI=0.47–0.71, p<.001) compared to those who dual used (14.2%). There was no significant difference in reporting a history of a single MHC among those exclusively vaping (16.7%, AOR=1.01, 95% CI= 0.77–1.32, p=.965), those exclusively smoking (15.3%, AOR=0.85, 95% CI=0.68–1.07, p=.172) and those dual using (14.2%). Those who were not currently smoking or vaping (13.8%, AOR=0.31 95% CI=0.26–0.36, p<.001), exclusively vaping (30.4%, AOR=0.78 95% CI=0.63–0.97, p=.028), or exclusively smoking (27.2%, AOR=0.67 95% CI=0.56–0.80, p<.001), were significantly less likely to report a history of multiple MHCs compared to those dual using (36.8%) (Table 2). Associations between dual use prevalence and psychological distress were broadly similar to those for MHC (Table 2). Dual use was most prevalent among those with a history of a personality disorder (14.7%), a substance misuse disorder (12.6%), or psychosis (12.1%) (Additional file 2 table_S2).
Among those who dual used, those who vaped non-daily and those who vaped 1–4 times a day were less likely to report a single MHC than those who vaped daily and those who vaped over 12 times a day. Those who vaped 12–19 mg/mL of nicotine were significantly less likely to report a history of multiple MHCs than those who vaped 20 mg/mL or more (Additional file 2 table_S8).
Sensitivity analyses
When ‘don’t know’ responses were included as a MHC or excluded from analyses, those who vaped less than 12 times a day were significantly less likely to have multiple MHCs than those who vaped more than 12 times a day. The interpretation of all other analyses did not differ in sensitivity analyses (Additional file 2 table_S9).
When people who smoked ‘other’ tobacco were included in smoking prevalence analysis, the interpretation of associations between those who currently smoked tobacco cigarettes and MHCs and distress did not change. Those who were smoking ‘other’ forms of tobacco were more likely to report a history of single or multiple MHCs compared to people who have never smoked tobacco; but, less likely to report a history of multiple MHCs than people who smoked tobacco cigarettes (AOR=1.58, 95% CI=1.23–2.05; p<.001, data not shown) (Additional file 2 table_S10).
People who smoked ‘other’ tobacco were also more likely to report past month moderate or serious psychological distress than those who had never smoked tobacco, but there was no difference from people who smoked tobacco cigarettes (AOR=1.15, 95% CI=0.82–1.62; p=.422, data not shown) (Additional file 2 table_S10).
Discussion
This study reports on vaping and smoking characteristics among those with a history of single or multiple MHCs or experiencing past month psychological distress in England. It also presents these characteristics by mental health diagnosis. Smoking, vaping and dual use were substantially higher among those with a history of MHCs, especially multiple MHCs, and experiencing past-month distress.
Findings that those with a history of a single or multiple MHCs and psychological distress were more likely to smoke, were heavier smokers and show greater signs of dependence than those without are in line with previous findings [6, 8, 16, 21]. We also report higher levels of vaping among those with MHCs and or moderate-serious psychological distress. Unlike smoking, there were few associations between vaping characteristics and MHCs; however, there were some associations between psychological distress and disposable e-cigarette use and higher nicotine concentrations.
Although rates of vaping were higher among people with MHC and distress, sample sizes were still small when broken down into vaping characteristics subgroups. Therefore, it may be that sample sizes were too small to detect effects. As we found significant effects of multiple MHCs on vaping prevalence, it is likely that there are effects of interactions between MHCs. Therefore, vaping among people with MHCs should not be interpreted on a solely individual level but with acknowledgement of comorbidities. It is also important to consider how combinations of different MHCs may influence vaping. The diagnosis of certain disorders, such as alcohol use disorder, is strongly correlated with the other specific MHCs, such as depression, which is also strongly associated with smoking [14]. Therefore, it may be that associations between multiple MHCs and vaping are due to certain MHCs being associated with vaping, and independently also being associated with a secondary MHC diagnosis.
Current vaping was most prevalent among those with a history of substance misuse disorder, or a severe MHC such as personality disorder, or psychosis. However, many of these people who were vaping were also smoking, with exclusive vaping being quite low among these groups. Vaping characteristics also seemed to differ among clusters of MHCs. Those with a severe MHC had fewer vaping sessions per day, but used high nicotine concentrations. However, the sample sizes were too small to make meaningful comparisons. Differences in characteristics between diagnoses are likely influenced by current or previous smoking. However, this may also be due to participants’ interactions with a range of different mental health services and potentially different approaches to smoking cessation, vaping and types of vaping products provided or suggested by these services [31].
It is unclear the extent to which nicotine is implicated in the association between smoking, vaping, MHCs and distress. Similar to our findings among people exclusively vaping, previous research has reported that among those who formerly smoked, nicotine product use was associated with greater psychological distress compared to no nicotine use [32]; however, this differed by product used and was affected significantly by sociodemographic confounders.
Dual use was higher among people with MHCs and psychological distress than those without, which is in line with previous research [33]. Dual use was also significantly more prevalent among people with a history of two or more MHCs or past month serious distress than exclusive vaping or exclusive smoking. This may be due to people with MHCs and past month psychological distress trying to transition from smoking to vaping, but struggling to fully quit smoking, or people with MHC and past month psychological distress vaping when they are in a location where smoking is not allowed, such as in hospital [34].
The present study has several limitations, firstly the use of repeat cross-sectional data means that we cannot infer direction of the association between MHCs, psychological distress and smoking and vaping. Moreover, questions on MHCs relied on self-report therefore may be less accurate than if more established measures or linked health record data was used. Those with a history of multiple MHCs may also have been diagnosed with MHCs at distinctly different time points, therefore a history of multiple MHCs may not represent current comorbidity. Relationships between the likelihood of different MHC diagnoses are not independent.
Finally, although psychological distress and MHC diagnosis measure different concepts, there is substantial overlap between the two [28]. Not all the participants reporting MHCs also reported past month psychological distress, and just under a fifth of participants reporting moderate or serious distress had no history of MHCs. However, psychological distress questions were asked concerning the past 30 days, while MHC questions were asked about every diagnosis. Therefore, the temporal differences may mean that they are less comparable and should be considered separately.
The association between comorbid mental health and smoking and vaping is complex and needs greater investigation. Future research should investigate if certain clusters of comorbid MHCs are associated with smoking and vaping, and how stop smoking interventions can help these specific groups. Future research should also explore dual use among those with MHCs and psychological distress and how targeted interventions can help people transition from dual use to exclusive vaping and/or use of other cessation aids to completely stop tobacco cigarette smoking.
Conclusions
In conclusion, smoking was higher among those with a history of MHCs, especially among those with multiple MHCs, and experiencing past month psychological distress. Those with a history of MHCs and those with current psychological distress were heavier smokers with greater dependence on smoking. Vaping was less common than smoking although vaping was also higher among those with a history of MHCs and experiencing distress. Dual use was also higher than exclusive vaping and smoking.
Acknowledgements
We thank all the survey participants.
Twitter:
Eve Taylor @EveTaylor22
King’s College London Nicotine Research Group @KingsNRG
UCL Tobacco and Alcohol Research Group @UCL_TARG
Jamie Brown @jamiebrown10
Declarations
Ethics approval and consent to participate
Ethical approval for the STS is granted by the UCL Ethics Committee (ID 0498/001). The inclusion of the mental health module was approved by the same committee (2808/005). In accordance with ethical approval, all respondents were given a written information sheet about the study and provide informed verbal consent.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no known conflicts of interest. JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.